BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $13.58, for a total transaction of $135,800.00. Following the completion of the transaction, the chief financial officer now directly owns 162,942 shares in the company, valued at approximately $2,212,752. BioCryst Pharmaceuticals, Inc. … Continue reading Big Movers : BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eastman Chemical Co. (NYSE:EMN), Pike Corporation (NYSE:PIKE), General Motors Company (NYSE:GM)